A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma
Clinical trial NCT05751928 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05751928
- Sponsor
- Biocad
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-04-05
- Primary completion
- 2027-01-01
- Enrollment
- 411
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.